AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
2.890
+0.160 (5.86%)
At close: Nov 4, 2024, 4:00 PM
2.740
-0.150 (-5.19%)
Pre-market: Nov 5, 2024, 9:14 AM EST
AbCellera Biologics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Net Income | -175.8 | -146.4 | 158.52 | 153.46 | 118.92 | -2.21 | Upgrade
|
| Depreciation & Amortization | 92.21 | 30.89 | 24.7 | 17.25 | 5.27 | 1.85 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | 8.4 | - | - | - | Upgrade
|
| Stock-Based Compensation | 68.8 | 64.18 | 49.48 | 30.65 | 8.4 | 0.89 | Upgrade
|
| Other Operating Activities | -66.05 | -5.78 | 6.43 | 1.55 | 6.81 | 0.19 | Upgrade
|
| Change in Accounts Receivable | -64.7 | -36.66 | 106.46 | 22.48 | -203.02 | -1.8 | Upgrade
|
| Change in Accounts Payable | -9.23 | -15.1 | -2.09 | -3.24 | 6.6 | 0.15 | Upgrade
|
| Change in Unearned Revenue | 19.6 | 25.55 | 15.45 | 39.34 | 15.05 | -0.01 | Upgrade
|
| Change in Income Taxes | -6.93 | 30.46 | -88.61 | -13.53 | 36.41 | - | Upgrade
|
| Change in Other Net Operating Assets | 21.92 | 8.98 | -1.38 | -3.38 | 28.26 | 3.63 | Upgrade
|
| Operating Cash Flow | -120.17 | -43.88 | 277.36 | 244.58 | 22.69 | 2.69 | Upgrade
|
| Operating Cash Flow Growth | - | - | 13.40% | 977.94% | 742.24% | -24.43% | Upgrade
|
| Capital Expenditures | -77.2 | -76.95 | -70.66 | -58.45 | -9.67 | -4 | Upgrade
|
| Cash Acquisitions | - | - | - | -11.46 | -87.64 | - | Upgrade
|
| Sale (Purchase) of Intangibles | -0.56 | -0.56 | -2 | - | -5 | - | Upgrade
|
| Investment in Securities | 99.7 | -168.91 | -296.4 | -294.96 | -17.46 | - | Upgrade
|
| Other Investing Activities | 39.44 | 25.31 | 16.43 | 32.62 | - | -1.78 | Upgrade
|
| Investing Cash Flow | 61.38 | -221.11 | -352.63 | -332.25 | -119.78 | -5.78 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | - | 0.39 | Upgrade
|
| Long-Term Debt Issued | - | 11.59 | 2.76 | 5.49 | 89.99 | 0.19 | Upgrade
|
| Total Debt Issued | 12.63 | 11.59 | 2.76 | 5.49 | 89.99 | 0.58 | Upgrade
|
| Long-Term Debt Repaid | - | - | - | - | -19.94 | -0.4 | Upgrade
|
| Total Debt Repaid | - | - | - | - | -19.94 | -0.4 | Upgrade
|
| Net Debt Issued (Repaid) | 12.63 | 11.59 | 2.76 | 5.49 | 70.05 | 0.18 | Upgrade
|
| Issuance of Common Stock | 0.5 | - | - | - | 539.33 | 0.03 | Upgrade
|
| Other Financing Activities | -0.74 | -1.23 | -4.38 | -9.37 | -0.39 | -0.01 | Upgrade
|
| Financing Cash Flow | 12.39 | 10.36 | -1.63 | -3.89 | 683.65 | 0.2 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.61 | 0.59 | -9.6 | -1.43 | - | - | Upgrade
|
| Net Cash Flow | -45.78 | -254.04 | -86.49 | -92.97 | 586.56 | -2.89 | Upgrade
|
| Free Cash Flow | -197.36 | -120.82 | 206.7 | 186.13 | 13.02 | -1.3 | Upgrade
|
| Free Cash Flow Growth | - | - | 11.05% | 1329.91% | - | - | Upgrade
|
| Free Cash Flow Margin | -598.76% | -317.75% | 42.58% | 49.61% | 5.58% | -11.22% | Upgrade
|
| Free Cash Flow Per Share | -0.67 | -0.42 | 0.66 | 0.58 | 0.05 | -0.01 | Upgrade
|
| Levered Free Cash Flow | -105.07 | -102.96 | 205.62 | 143.8 | -24.06 | -3.23 | Upgrade
|
| Unlevered Free Cash Flow | -105.07 | -102.96 | 205.62 | 143.8 | -19.8 | -3.1 | Upgrade
|
| Change in Net Working Capital | -8.84 | -27.72 | -63.53 | -26.6 | 116.32 | -0.74 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.